![Page 1: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/1.jpg)
Omega-3 and Coronary Heart Disease Biomarkers and Interventions
William S. Harris, PhD
President OmegaQuant Analytics
Sioux Falls, SD
Research Professor of Medicine Sanford School of Medicine University of South Dakota
Senior Scientist Health Diagnostic Lab, Inc.
Richmond, VA
![Page 2: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/2.jpg)
Summary
Achieving optimal RBC levels of omega-3 fatty acids can help reduce
risk for cardiovascular disease
![Page 3: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/3.jpg)
Objectives
1. Define 5 fatty acid classes in RBC’s
2. Describe how fatty acid status is assessed
3. Explain how RBC fatty acids relate to cardiovascular risk
4. Discuss mechanisms of action
5. Review recommended fatty acid intakes
![Page 4: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/4.jpg)
Take Home Messages 1. The RBC membrane contains >20 individual fatty acids of 5
different classes
2. The RBC EPA+DHA content (the Omega-3 Index) is a valid and stable biomarker of omega-3 fatty acid status
3. For cardiovascular health, an Omega-3 Index >8% is optimal and an Index < 4% is deficient. Target trans fat levels are <1%.
4. Dietary doses of EPA+DHA reduce risk for CHD via non-traditional pathways by changing membrane physiochemical properties and improving the eicosanoid profile. Pharmacologic doses lower triglycerides.
5. Omega-3 EPA+DHA intakes should be 400-500 mg/day for most adults and twice that for CHD patients.
![Page 5: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/5.jpg)
Objectives
1. Define 5 fatty acid classes in RBC’s
2. Describe how fatty acid status is assessed
3. Explain how RBC fatty acids relate to cardiovascular risk
4. Discuss mechanisms of action
5. Review recommended fatty acid intakes
![Page 6: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/6.jpg)
Omega-6
Polyunsaturated Fatty Acids Non-Essential Fatty Acids
Omega-3
Polyunsaturated Fatty Acids
COOH Elaidic acid (EA)
C18:1n-9 trans; Trans Fatty Acid
Eicosapentaenoic acid, EPA C20:5n-3
COOH
-Linolenic acid (ALA) C18:3n-3
COOH COOH
Palmitic acid (PA) C16:0 Saturated Fatty Acid
COOH
Oleic acid (OA) C18:1n-9 Monounsaturated Fatty Acid
COOH
Arachidonic acid (AA) C20:4n-6
COOH -Linolenic acid (GLA) C18:3n-6
COOH
Linoleic acid (LA) C18:2n-6
Docosahexaenoic acid, DHA C22:6n-3
COOH
Types of Fatty Acids
α ω
A fatty acid is a chain of carbon atoms with an acid group on one end • Saturated • Monounsaturated • Polyunsaturated – Omega-6 and Omega-3 (n-6 or n-3) • Trans
![Page 7: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/7.jpg)
• PUFA have >1 double bond; n-6 and n-3 families.
• Major n-6 PUFAs: linoleic acid (LA, C18:2n-6) and arachidonic acid (AA, C20:4n-6).
•All n-6 PUFAs can be synthesized from LA, but LA cannot be made de novo (i.e., essential).
• Linoleic - vegetable oils (corn, safflower, soybean, etc.) with small amounts in canola, olive and flaxseed oils. Arachidonic - only in animal products like meat and eggs (but not in dairy products).
Types of Fatty Acids N-6 Polyunsaturates (PUFAs)
![Page 8: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/8.jpg)
• Major n-3 PUFAs are alpha-linolenic acid (ALA, C18:3n-3), eicosapentaenoic acid (EPA; C20:5n-3), docosapentaenoic acid (DPA; C22:5n-3) and docosahexaenoic acid (DHA; C22:6n-3)
• All n-3 PUFAs can be synthesized from ALA, but ALA cannot be made de novo (i.e., essential).
• ALA is in certain plant oils (canola, olive and flaxseed), whereas EPA and DHA come from seafoods.
Types of Fatty Acids N-3 Polyunsaturates
![Page 9: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/9.jpg)
Take Home Message
The RBC membrane contains >20 individual fatty acids of 5
different classes
![Page 10: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/10.jpg)
Objectives
1. Define 5 fatty acid classes in RBC’s
2. Describe how fatty acid status is assessed
3. Explain how RBC fatty acids relate to cardiovascular risk
4. Discuss mechanisms of action
5. Review recommended fatty acid intakes
![Page 11: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/11.jpg)
Assessing Fatty Acid Status
RBC fatty acids are hydrolyzed from membranes, derivatized and analyzed by gas chromatography
![Page 12: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/12.jpg)
Assessing Fatty Acid Status The Omega-3 Index
A measure of the amount of EPA+DHA in red blood cell membranes expressed as the percent of total fatty acids
Harris WS and von Schacky C. Prev Med 2004;39:212-220.
There are 64 fatty acids in this model membrane, 3 of which are EPA or DHA
3/64 = 4.6%
Omega-3 Index = 4.6%
![Page 13: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/13.jpg)
Assessing Fatty Acid Status Low Biological Variability & Long-Term Marker
Plasma EPA+DHA
Harris and Thomas. Clin Biochem 2010;43:338–340
20 healthy volunteers tested weekly for 6 weeks Total Coefficients of Variability (CVs)
EPA+DHA in… • RBC = 4.1% • Whole Blood = 6.7% • Plasma = 16% • Plasma PL = 15%
0%
1%
2%
3%
4%
5%
6%
7%
8%
9%
10%
Pe
rce
nt
of
tota
l FA
s
0%
2%
4%
6%
8%
10%
12%
Week 0 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6
Pe
rce
nt
of
tota
l FA
s
Pla
sma
RB
C
RBC EPA+DHA
![Page 14: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/14.jpg)
Take Home Message
The RBC EPA+DHA content (the Omega-3 Index) is a valid and stable
biomarker of omega-3 fatty acid status
![Page 15: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/15.jpg)
Objectives
1. Define 5 fatty acid classes in RBC’s
2. Describe how fatty acid status is assessed
3. Explain how RBC fatty acids relate to cardiovascular risk
4. Discuss mechanisms of action
5. Review recommended fatty acid intakes
![Page 16: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/16.jpg)
![Page 17: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/17.jpg)
RBC Fatty Acids and CVD Risk
Strong evidence • Omega-3 Index: Low levels = High risk Intermediate evidence • Trans fats: High levels = High risk • Linoleic acid (n-6): Low levels = High risk Little evidence • Saturated • Monounsaturated • Plant n-3 (α-linolenic acid)
![Page 18: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/18.jpg)
Selecting Omega-3 Index Targets
GISSI-P:~9–10%
Greatest Protection
Least Protection
10%
8%
6%
4%
2%
DART:~8–9%
CHS: 8.8%
SCIMO: 8.3%
5 epi studies:~8%
PHS: 7.3%
Seattle: 6.5%
PHS: 3.9%
SCIMO: 3.4%
Seattle: 3.3%
8.1%
Harris WS and von Schacky. Prev Med 2004;39:212-220.
RBC Fatty Acids and CVD Risk
![Page 19: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/19.jpg)
Omega-3 Index Risk Zones
Harris WS and von Schacky. Prev Med 2004;39:212-220.
8% 4%
Percent of EPA+DHA in RBC
Undesirable Desirable Intermediate Undesirable
Itomura, in vivo 2008;22:131-136.
Japan USA/EU
Risk for cardiac death in the US is 45x higher than in Japan
Iso et al. Circ 2006;113:195-202
He et al. Circ 2004;109:2705-2711
RBC Fatty Acids and CVD Risk
![Page 20: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/20.jpg)
Marchioli and Harris, unpublished
Norway Spain
Germany
Japan
Korea
Alaska
0%
2%
4%
6%
8%
10%
12%
14%
0 5 10 15 20 25
EPA+DHA
Healthy subjects Ill subjects
USA
Germany
Norway
Spain
Japan
Alaska
Korea
The Omega-3 Index Worldwide
![Page 21: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/21.jpg)
Omega-3 Index and Acute Coronary Syndromes (768 case-control pairs)
Multivariable logistic regression model including: age; race; gender; history of diabetes mellitus, hypertension, hyperlipidemia and/or myocardial infarction; a family history of coronary artery disease; and LDL-C, HDL-C, and triglycerides.
Block RC, et al. Atherosclerosis 2008;197 :821-828.
p=0.03
p=0.017
p<0.001
p for trend < 0.0001
RBC Fatty Acids and CVD Risk
![Page 22: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/22.jpg)
The Omega-3 Index and Cellular Aging
RBC Fatty Acids and CVD Risk
![Page 23: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/23.jpg)
Adapted from Farzanah-Far, et al. JAMA 2010;303:250-257
Blood Omega-3 is Inversely Associated with the Rate of Telomere Attrition
P<0.001 for trend
RBC Fatty Acids and CVD Risk
![Page 24: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/24.jpg)
Omega-3 Index and Time to Death in 982 CHD Patients
Pottala et al. Circ CV Outcomes & Qual 2010;3 406-412
< 4.6% ≥4.6%
< 4.6% ≥4.6%
1.2 yrs
It took 1.2 years longer for 20% of the population to die in the higher vs. the lower omega-3 group
RBC Fatty Acids and CVD Risk
![Page 25: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/25.jpg)
Why is the Omega-3 Index Target 8%?
• The average Omega-3 Index estimated from 11 studies was 8.1%
• An Omega-3 Index of >8% was associated with reduced probability for acute coronary syndrome compared to an Index of <4%
• The Omega-3 Index associated with the slowest rate of cellular aging was 8.7%
• The average Index in Japan (where CHD is rare) is 9-10%
RBC Fatty Acids and CVD Risk
![Page 26: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/26.jpg)
Adapted from Siscovick DS et al. JAMA 1995;274:1363-1367.
Odds R
atio
3.3%
Midrange RBC EPA+DHA by Quartile
4.3% 5.0% 6.5%
90% reduction in risk
*p<0.05
vs Q1
Clinical Evidence – Cross Sectional Primary Cardiac Arrest and the Omega-3 Index Seattle PCA Study
![Page 27: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/27.jpg)
3.6% 4.8% 5.6% 6.9%
Mean Blood Omega-3 FA (%) by Quartile
Clinical Evidence – Prospective Sudden Cardiac Death and the Omega-3 Index Physicians' Health Study
Albert CM et al. N Engl J Med 2002:346:1113-1118.
Rela
tive R
isk
90% reduction in risk
p for trend = 0.001
![Page 28: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/28.jpg)
The Omega-3 Index, Brain Volume and Cognitive Function in Framingham
Quartile 1 vs 2-4 (<4.4% vs above)
n=1575; age=67
Model Covariates Total Cerebral Brain Volume (%)
Visual Memory Executive
Function
Abstract Thinking
Lower Index = Smaller Volume Lower Index = Poorer Function
A Age, sex, education, time interval
p=0.005 p=0.026 p=0.025 p=0.001
B A with apoE4 and homocysteine
p=0.005 p=0.026 p=0.038 p=0.002
C B with physical activity and BMI
p=0.008 p=0.024 p=0.046 p=0.002
D
B with diabetes, sBP, smoking, A-fib,
prevalent CVD and total cholesterol
p=0.011 p=0.079 p=0.108 p=0.001
Tan Z, et al. Neurology 2012
“The MRI finding of lower brain volume [in those with an Omega-3 Index <4.4%] represents a change
equivalent to approximately 2 years of structural brain aging.”
![Page 29: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/29.jpg)
Johnston et al. Nutr Neurosci 2012 (in press)
Executive Functioning and Cognitive Flexibility by Quartile of the HS-Omega-3 Index in Army Members
Deployed in Iraq
P<0.01 for trend
0
20
40
60
80
100
120
1 2 3 4
Executive Function Score
Cognitive Flexibility Score
Sta
nd
ard
ized
Test
Sco
res
Omega-3 Quartile
N=78, mean age 31 yrs
![Page 30: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/30.jpg)
Take Home Message
For cardiovascular (and possibly neurocognitive) health, an Omega-3 Index >8% is optimal and an Index <
4% is deficient.
![Page 31: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/31.jpg)
Objectives
1. Define 5 fatty acid classes in RBC’s
2. Describe how fatty acid status is assessed
3. Explain how RBC fatty acids relate to cardiovascular risk
4. Discuss mechanisms of action
5. Review recommended fatty acid intakes
![Page 32: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/32.jpg)
Effects of Omega-3*… • Reduced heart rate • Reduced inflammation • Improved vascular function • Reduced susceptibility to cardiac arrhythmias
Mediated by…. • Altered cell membrane physiochemical properties • Shifts in eicosanoid production • Altered gene expression
Mozaffarian and Wu. JACC 2011; 58:2047–67 * Primarily from nutritionally-achievable intakes: 500-1,000 mg/d
![Page 33: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/33.jpg)
Take Home Message
Dietary doses of EPA+DHA reduce risk for CHD via non-traditional
pathways by changing membrane physiochemical properties and
improving the eicosanoid profile. Pharmacologic doses lower
triglycerides.
![Page 34: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/34.jpg)
Objectives
1. Define 5 fatty acid classes in RBC’s
2. Describe how fatty acid status is assessed
3. Explain how RBC fatty acids relate to cardiovascular risk
4. Discuss mechanisms of action
5. Review recommended fatty acid intakes
![Page 35: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/35.jpg)
AHA Scientific Statement on Omega-3s
Population Recommendation
Patients without documented CHD
Eat a variety of fish (preferably oily) at least twice a week*, include oils and foods rich in ALA
Patients with documented CHD
Consume ~1 gm of EPA+DHA per day, preferably from fish, supplements could be used in consultation with a physician
Patients needing TG lowering
2 – 4 gm of EPA+DHA per day provided as capsule under a physician’s care
Kris-Etherton, Harris, & Appel. Circulation, 2002;106:2747-57.
*Equal to about 400-500 mg EPA+DHA/day
![Page 36: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/36.jpg)
AHA Recommendations for Women
Population Recommendation
Women with high blood cholesterol or triglycerides; for primary or secondary prevention
Consumption of omega-3 fatty acids in the form of fish or capsules (e.g., EPA 1800 mg/d)
Mosca et al. Circulation 2011;123:1243-6.
![Page 37: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/37.jpg)
Our tests of 16 leading pill brands found that all contained roughly as much omega-3s as their labels claimed, and none were contaminated or spoiled. So choose them based mainly on price
![Page 38: Omega-3 and Coronary Heart Disease Biomarkers and Interventionsrmalab.com/sites/default/files/files/FattyAcidWebinar_Dr... · 2019-04-10 · Omega-3 and Coronary Heart Disease . Biomarkers](https://reader031.vdocument.in/reader031/viewer/2022041817/5e5b9e080168b171161d0d32/html5/thumbnails/38.jpg)
Take Home Messages 1. The RBC membrane contains >20 individual fatty acids of 5
different classes
2. The RBC EPA+DHA content (the Omega-3 Index) is a valid and stable biomarker of omega-3 fatty acid status
3. For cardiovascular health, an Omega-3 Index >8% is optimal and an Index < 4% is deficient. Target trans fat levels are <1%.
4. Dietary doses of EPA+DHA reduce risk for CHD via non-traditional pathways by changing membrane physiochemical properties and improving the eicosanoid profile. Pharmacologic doses lower triglycerides.
5. Omega-3 EPA+DHA intakes should be 400-500 mg/day for most adults and twice that for CHD patients.